GI, Colorectal

Colon cancer and rectum cancer are the second leading causes of cancer death in women and men combined. However, caught early enough, colon and rectal cancers can be prevented, treated, or cured.

Fewer than half of people found to have colorectal cancer are diagnosed at an early stage when treatment is most effective. This means that many people are living with a serious risk that they are not aware of. Screening offers greater peace of mind.

InSure ONE is a fecal immunochemical test (FIT) that qualitatively detects human hemoglobin from blood in fecal samples, which may be an indication of lower gastrointestinal bleeding associated with disorders such as diverticulitis, ulcerative colitis, polyps, colorectal cancers, or large adenomas that bleed.

The AmeriPath national network of board-certified pathologists provides comprehensive gastrointestinal pathology services utilizing state-of-the-art technologies including immunohistochemistry and molecular diagnostics.

Our nationally recognized GI pathology and liver disease expertise combined with the delivery of world-class GI services in your community ensures you receive accurate and decisive diagnostic, prognostic, and therapeutic information promptly and in a cost-effective manner.

Learn more at: Gastroenterology – AmeriPath®: Anatomic Pathology Services

The Quest Advanced Oncology ColonSEQ Panels, part of our comprehensive solution for colon cancer, are disease-targeted next-gen sequencing (NGS) panels. Our ColonSEQ panels are part of the decision-support tools that we’ve developed to help physicians create a treatment plan for navigating within standard of care and clinical trial options, based on mutations found in the patient’s tumor.